Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Prediction in Adolescent and Adult Depression
NCT00106197Phase 4Unknown
- Start
- Jun 2004
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bupropion in major depressive disorder (MDD) and persistent depressive disorder (PDD). Primary endpoint: Reduction in depressive symptoms. Status: unknown.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on NCT00106197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00106197.